Prof Martin Dreyling discusses the safety profile of the BTK inhibitor acalabrutinib in patients with mantle cell lymphoma.

The real-world data showed lower rates of atrial fibrillation and hypertension associated with the second-generation Bruton ...

A significant number of patients taking Bruton tyrosine kinase inhibitors (BTKis) for chronic lymphocytic leukemia (CLL) ...

Latest preliminary data show continued promising clinical activity in NHL patients, with two complete responses (CR), three ...

Calquence (acalabrutinib) plus bendamustine and rituximab reduced risk for disease progression or death by 27% compared with ...

AstraZeneca (LSE:AZN) recently experienced positive developments, including the European approval of Calquence for mantle cell lymphoma and promising Phase III trial results for ENHERTU in breast ...

Cambridge: AstraZeneca has announced that Calquence (acalabrutinib) in combination with bendamustine and rituximab has been approved in the European Union for the treatment of adult patients with ...

The European Commission (EC) has approved AstraZeneca's Bruton's tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib), ...

AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been approved in the European Union (EU) for the treatment of adult patients with previously untreated mantle ...

AstraZeneca’s Calquence is being assessed as part of a comprehensive clinical development programme. Credit: © AstraZeneca 2025. The European Commission (EC) has ...